Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...
Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the DESTINY-Breast04 trial data, but adding the DESTINY-Breast06 data to the label ...
India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a ...
3d
Zacks.com on MSNAstraZeneca Rises Almost 9% in a Month: How to Play the StockAstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.
Researchers have seen an 'alarming' rise in breast cancer rates in women under 40, with some states experiencing a 32% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results